Eating disorders psychedelic and ketamine research trials
Data as of 11 October 2026. Source: ClinicalTrials.gov records held by PsychoactiveMap, refreshed from a reviewed snapshot.
11 registered studies are counted for eating disorders. By compound: 7 psilocybin, 2 MDMA and 2 ketamine. By registry status: 3 recruiting, 1 enrolling by invitation, 6 completed and 1 withdrawn. By phase: 4 phase 1 and 7 phase 2. Reported start years run from 2019 (earliest) to 2026 (latest).
This page includes anorexia nervosa, bulimia and binge eating disorder when the title names them. Cancer-related anorexia and cachexia are not matched. Studies are matched by keyword on the title as registered, so a study can be missed and a study that mentions the condition only in passing can be included. A study tagged with more than one compound is counted under each compound. Ketamine studies are counted only when PsychoactiveMap classifies them as psychiatric research; anaesthesia, sedation and pain studies are left out.
Educational information, not medical advice. A registry listing is not evidence of safety, benefit or results, and it is not a recommendation. PsychoactiveMap does not recruit, screen or refer participants. Status and other details are copied from the registry and can be out of date, so check the registry record and speak to a qualified health professional before any decision. Read the full disclaimer.
At a glance
- 11 registered studies are counted on this page.
By compound
| Compound hub | Studies |
|---|---|
| Psilocybin | 7 |
| MDMA | 2 |
| Ketamine | 2 |
By registry status
| Status | Studies | Share |
|---|---|---|
| Recruiting | 3 | 27% |
| Enrolling by invitation | 1 | 9% |
| Completed | 6 | 55% |
| Withdrawn | 1 | 9% |
By phase
| Phase | Studies | Share |
|---|---|---|
| Phase 1 | 4 | 36% |
| Phase 2 | 7 | 64% |
Countries
Country is taken from the study's linked research site. 0 of 11 records have no country on file. The top 3 countries are shown.
| Country | Studies | Share |
|---|---|---|
| United States | 9 | 82% |
| United Kingdom | 1 | 9% |
| Sweden | 1 | 9% |
When studies started
| Start year | Studies |
|---|---|
| 2024 to 2026 | 5 |
| 2020 to 2023 | 5 |
| 2015 to 2019 | 1 |
Study design
- 11 interventional and 0 observational studies.
- Median planned or actual enrolment is 22 participants (range 5 to 40, across 10 records that report it).
Registered studies
All counted studies, newest start first. The order is not a ranking and says nothing about quality. Titles are quoted from the registry. Each ID links to its own ClinicalTrials.gov record, which has the eligibility criteria and contacts.
| Title as registered | Registry ID | Status | Phase | Start | Compound |
|---|---|---|---|---|---|
| MDMA Assisted Therapy for BN | NCT07542145 | Recruiting | Phase 1 | 2026-05-01 | MDMA |
| A Multi-Site Study of MDMA-Assisted Psychotherapy for Eating Disorders | NCT04454684 | Withdrawn | Phase 2 | 2026-02-01 | MDMA |
| Safety, Therapeutic Potential, and Mechanisms of Two Psilocybin Doses, Administered With Psychological Support in Young Adults With Anorexia Nervosa | NCT07169747 | Recruiting | Phase 2 | 2025-10-01 | Psilocybin |
| Ketamine Effects on Learning In Eating Disorders | NCT06736769 | Enrolling by invitation | Phase 2 | 2025-06-05 | Ketamine |
| Study of Psilocybin for Anorexia in Young Adults | NCT06399263 | Recruiting | Phase 2 | 2024-11-18 | Psilocybin |
| Efficacy and Safety of COMP360 Psilocybin Therapy in Anorexia Nervosa: a Proof-of-concept Study | NCT05481736 | Completed | Phase 2 | 2022-10-12 | Psilocybin |
| Evaluation of Psilocybin (TRP-8802) in the Treatment of Binge Eating Disorder | NCT05035927 | Completed | Phase 2 | 2022-03-16 | Psilocybin |
| Psilocybin as a Treatment for Anorexia Nervosa: A Pilot Study | NCT04505189 | Completed | Phase 1 | 2021-05-28 | Psilocybin |
| Evaluation of Psilocybin in Anorexia Nervosa: Safety and Efficacy | NCT04661514 | Completed | Phase 2 | 2021-05-01 | Psilocybin |
| Modified Ketogenic Diet and Ketamine for Anorexia Nervosa | NCT04714541 | Completed | Phase 1 | 2021-04-12 | Ketamine |
| Effects of Psilocybin in Anorexia Nervosa | NCT04052568 | Completed | Phase 1 | 2019-08-26 | Psilocybin |
About this data
Compound tags come from automated matching of the registry search term and have not been checked record by record. Counts are of registered studies, not of people, results or approvals. A registry listing is not evidence of safety, benefit or results.
Substance hubs for these compounds
Psilocybin | MDMA | Ketamine
Other condition hubs
Depression | Treatment-resistant depression | Bipolar disorder | Post-traumatic stress disorder | Alcohol use disorder | Opioid use disorder | Tobacco and nicotine use | Cocaine and methamphetamine use | Anxiety | Cancer and end-of-life distress | Obsessive-compulsive disorder | Headache and migraine | Chronic pain | Suicidal ideation and suicide risk